MOTS-c half life: what's actually known about how long it lasts

Last updated 2026-07-25

What is MOTS-c's half life in humans?

Nobody has published a peer-reviewed human half-life figure for MOTS-c. That's the honest, unsatisfying answer, and it's the first thing worth knowing before you read anything else about dosing schedules. The original characterization of MOTS-c as a mitochondrial-derived peptide that improves metabolic homeostasis and reduces obesity and insulin resistance came from mouse work published in Cell Metabolism in 2015 ^[1]. That paper, and nearly everything that followed it, measured MOTS-c's effects on glucose handling, AMPK activation, and body weight in rodents, not its clearance rate in human plasma. A 2023 review in Frontiers in Endocrinology frames MOTS-c as "a promising mitochondrial-derived peptide for therapeutic exploitation" ^[2], which is a useful phrase because it's honest about where the peptide actually sits: promising, not proven, and still mostly preclinical. If a clinical pharmacokinetics trial with a defined human half-life existed, it would be the single most-cited paper in the MOTS-c literature. It isn't, because it hasn't been done. What you'll find instead, all over forums and vendor sites, are half-life numbers presented with confident precision ("MOTS-c has a half-life of X hours"). Treat those numbers as unsourced until someone can point you to the actual paper and table. As of now, that paper doesn't exist in the indexed literature this article draws from.

Why don't we have solid pharmacokinetic data for MOTS-c yet?

Because the research program is still in its early-to-middle innings, and pharmacokinetics is usually one of the later steps, not the first one. Researchers have spent the last decade mapping what MOTS-c does mechanistically, not how fast it disappears from blood after injection. The mechanistic picture is actually quite mature. A 2018 Cell Metabolism study showed that MOTS-c translocates to the nucleus under metabolic stress and directly regulates nuclear gene expression, including antioxidant response genes ^[3]. A 2019 BioEssays review calls it "a mitochondrial-encoded regulator of the nucleus" ^[4], summarizing how a 16-amino-acid peptide encoded in mitochondrial DNA ends up acting like a transcription factor. That's genuinely interesting biology, and it explains why so much lab attention has gone into signaling pathways (AMPK, Nrf2, CK2) rather than clearance kinetics. The practical reason human PK studies lag is straightforward: they're expensive, they require an IND-type framework or equivalent human research infrastructure, and MOTS-c has no FDA-approved drug product to anchor that work. You can check that yourself against Drugs@FDA, the FDA's own database of approved drug products ^[5]; MOTS-c isn't in it. Until a sponsor runs a formal human trial with serial blood draws and mass spec quantification, half-life estimates in humans are just guesses dressed up as facts.

What do animal studies suggest about how MOTS-c behaves after dosing?

Animal studies tell us MOTS-c acts fast at the level of cell signaling, and that it works whether given peripherally or produced endogenously during stress, but almost none of them report a formal half-life in minutes or hours. The 2015 Cell Metabolism paper found that MOTS-c treatment in mice improved insulin sensitivity and reduced diet-induced obesity, with effects on AMPK activation that are consistent with fast-acting signaling rather than slow accumulation ^[1]. The 2018 nuclear translocation paper showed MOTS-c enters the nucleus specifically in response to metabolic stress, implying a dynamic, responsive system rather than a peptide that just sits at steady levels ^[3]. A 2022 Diabetes & Metabolism Journal paper on exercise, mitohormesis, and MOTS-c ^[6] describes how circulating MOTS-c rises with exercise, which tells you the peptide is cleared and regenerated on a timescale relevant to a single workout, hours, not days, but again, this is a pattern inference, not a measured elimination half-life. A separate 2021 paper specifically reviewing mitochondrial-derived peptides and exercise reinforces that exercise-induced changes in circulating MOTS-c happen acutely ^[7]. None of this substitutes for an actual PK study with timed blood draws after a known dose. It's circumstantial evidence that MOTS-c turns over relatively quickly in response to physiological triggers, which is a different claim than "the half-life is N hours."

How does MOTS-c's half life compare to other peptides people use for metabolic health?

Short answer: we don't have a real number to put MOTS-c in that comparison table yet, and that itself is the useful data point. Many peptides marketed alongside MOTS-c (in the self-administration and biohacking space) do have published human or animal half-life data because they went through, or are going through, formal drug development. MOTS-c has not been through that pipeline. A 2026 Sports Medicine review on the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance ^[8] is a useful frame here: it groups peptides into those with regulatory approval and pharmacokinetic characterization, and those circulating in gray-market use without it. MOTS-c sits in the second category.

This table isn't about ranking effectiveness. It's about ranking evidence maturity, and on that axis, MOTS-c is behind approved drugs by a wide margin. If you're comparing MOTS-c to something else on a dosing basis, be honest that you're comparing a rodent-dosed peptide to a human-dosed drug.

Does MOTS-c's half life change with exercise or metabolic stress?

The pattern in the literature suggests circulating MOTS-c levels shift with metabolic and physical stress, but that's a statement about concentration changes over time in response to a stimulus, not a formal half-life measurement. The 2022 Diabetes & Metabolism Journal review on exercise, mitohormesis, and MOTS-c ^[6] lays out the general concept: MOTS-c is part of a mitohormetic signaling loop, meaning mild mitochondrial stress (like exercise) triggers MOTS-c release and nuclear signaling as an adaptive response. This is where the "exercise mimetic" framing in MOTS-c marketing originates, and it's worth being precise about what that framing does and doesn't mean. The claim, as often marketed, is that MOTS-c is close to "exercise in a pill." What the actual research shows is narrower: MOTS-c mimics some downstream signaling effects of exercise (AMPK activation, some transcriptional responses) in cell and rodent models. A 2025 Scientific Reports study found MOTS-c mimics exercise-associated signaling to combat diabetic liver fibrosis in an animal model, acting through the Keap1-Nrf2-Smad2/3 pathway ^[9]. That's a real, specific, mechanistic finding in a disease model, not a demonstration that injecting MOTS-c in a healthy human replicates a training session's cardiovascular, muscular, and metabolic adaptations. Nobody has run that head-to-head human comparison.

How is MOTS-c cleared from the body, and does that affect dosing frequency?

We don't have a published human clearance mechanism study for MOTS-c, so any statement about how it's metabolized or excreted in people is extrapolation, not established fact. What we do know is that MOTS-c is a small peptide (16 amino acids), and peptides of that size are generally cleared quickly by proteolysis and renal filtration in mammals, a pattern seen across many short peptides, not something specifically demonstrated for MOTS-c in a dedicated clearance study. That general peptide biology is likely part of why anecdotal dosing schedules for MOTS-c tend to involve frequent administration (several times per week) rather than a single monthly dose, but again, that's inference layered on general peptide pharmacology, not a MOTS-c-specific finding. If you're trying to figure out realistic dosing intervals, the more useful resource is how to take MOTS-c peptide, which lays out what's actually documented about administration patterns versus what's guesswork. Don't let a specific half-life number (that doesn't exist in the literature) drive your dosing decisions; let the absence of that number inform how cautious you are.

What does the lack of human half-life data mean for dosing decisions?

It means any specific dosing schedule you see ("inject every 3 days," "cycle for 8 weeks") is based on user reports and extrapolation from rodent studies, not on a measured human elimination curve, and you should weigh that accordingly. This matters practically. Drug dosing intervals are normally set using half-life data: you want peak concentration high enough to have an effect and trough concentration not so low that the effect disappears between doses. Without a human half-life, nobody, including anyone selling MOTS-c, can tell you with real precision what dosing interval hits that target. What's circulating as "the" MOTS-c protocol is really a consensus guess, refined by anecdote over several years, not a pharmacokinetically derived schedule. That doesn't necessarily mean the common protocols are wrong. It means the confidence people express about them is higher than the underlying data supports. If you want a fuller picture of what's actually measured in trials and animal studies versus what's assumed, see MOTS-c results: what the research shows.

Is MOTS-c legal to buy, and how does that affect what we know about it?

MOTS-c is not an FDA-approved drug, and its regulatory status affects why pharmacokinetic data is so thin: nobody has been required to generate it. Compounding pharmacies operate under two main FDA frameworks: 503A, which covers traditional pharmacy compounding, and 503B, which covers larger outsourcing facilities. Bulk drug substances used under 503A are governed by 21 CFR 216.23 ^[10], and those used under 503B fall under 21 CFR 216.24 ^[11]. The FDA maintains a bulk drug substances list for 503A compounding ^[12] and a separate current list of nominated substances ^[13]. Whether MOTS-c appears on these lists, and in what form, changes over time and is worth checking directly rather than trusting a static claim in any single article. Separately, 21 U.S.C. 353a governs the legal basis for pharmacy compounding generally ^[14]. None of this regulatory framework requires a sponsor to run human PK studies before a compounded product reaches a patient through a prescriber, which is a meaningful difference from FDA drug approval, where PK data (including half-life) is a required part of the application. That gap in requirements is a direct reason MOTS-c's human half-life remains unknown. If you're trying to source MOTS-c through a provider-reviewed route, working with a prescriber who coordinates with a pharmacy that operates under one of these frameworks is a different risk profile than buying "research peptide" vials online with no clinical oversight. MOTS-c Co reviews providers who work with pharmacy partners for this reason: it doesn't compound or manufacture anything itself, and it won't pretend the half-life question is settled just because a supply chain exists.

What does MOTS-c actually do in the body, separate from the half-life question?

MOTS-c has a genuinely wide range of documented biological activity across rodent and cell studies, spanning metabolism, muscle, bone, lung, liver, and even cancer biology, and it's worth separating "this peptide does interesting things in models" from "this peptide is a proven human therapy." On metabolism specifically: the foundational 2015 Cell Metabolism paper found MOTS-c reduces obesity and insulin resistance in mice ^[1]. A 2022 Pharmacological Research study found MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes mellitus model ^[15]. A 2025 Experimental & Molecular Medicine paper found MOTS-c prevents pancreatic islet cell senescence in a model of delayed diabetes ^[16]. On muscle: a 2024 iScience paper found MOTS-c directly binds and activates CK2 to modulate skeletal muscle function ^[17]. A 2021 paper in the American Journal of Physiology found MOTS-c reduces myostatin and muscle atrophy signaling ^[18]. A 2024 study in the same journal found MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration ^[19], and a 2022 Peptides paper found MOTS-c promotes muscle differentiation in vitro ^[20]. Beyond metabolism and muscle, researchers have found MOTS-c effects in ovarian cancer progression (2024, Advanced Science) ^[21], lung ischemia-reperfusion injury (2025, Redox Biology) ^[22], bone metabolism regulation (2023, Frontiers in Physiology) ^[23], osteoarthritis cartilage degradation (2025, Free Radical Biology & Medicine) ^[24], and hepatitis B viral infection response (2024, Gut) ^[25]. That range is real and it's part of why MOTS-c generates so much research interest. It's also exactly why you should be skeptical of any single claim ("exercise mimetic," "anti-aging," "fat loss peptide") that reduces this sprawling, mostly preclinical body of work down to one marketing line. For a fuller accounting of what's measured versus claimed, see MOTS-c results: what the research shows.

Should the missing half-life data change how you think about safety monitoring?

Yes, in a specific, practical way: without a known half-life, nobody can tell you exactly when MOTS-c is fully cleared from your system, which matters if you're trying to time blood work or interpret results. If you're getting labs done to check metabolic markers while using MOTS-c, understand that timing relative to your last dose is a variable nobody has calibrated for this peptide the way it's calibrated for, say, insulin or approved GLP-1 drugs. That's a genuine practical gap, not a minor technicality. For a more detailed walkthrough of what to actually monitor and how to think about lab timing, see MOTS-c and blood work. There's also a research thread worth flagging honestly: a 2018 Rejuvenation Research paper titled "Mitochondrial-Derived Peptides Exacerbate Senescence" ^[26] is a reminder that mitochondrial-derived peptides as a class aren't uniformly protective in every context studied; effects can be context-dependent. That's not a specific MOTS-c safety signal in humans, but it's a reason to stay skeptical of blanket "good for aging" claims until the human data catches up.

Frequently asked questions

What is the half-life of MOTS-c in humans?

There is no published, peer-reviewed human half-life value for MOTS-c as of this writing. Nearly all pharmacokinetic-adjacent data comes from rodent and cell studies, such as the foundational 2015 Cell Metabolism paper (PMID 25738459). Any specific number you see quoted online is not sourced to an indexed human clinical study.

How often should MOTS-c be dosed if the half-life is unknown?

Common self-administration schedules (often several times weekly) are based on anecdote and extrapolation from general peptide pharmacology, not a measured human elimination curve. See how to take MOTS-c peptide for what's actually documented versus assumed about dosing frequency.

Is MOTS-c cleared quickly or slowly from the body?

Based on its small size (16 amino acids), general peptide biology suggests fast clearance via proteolysis and renal filtration, similar to other short peptides. This is inference from peptide chemistry generally, not a MOTS-c-specific clearance study measured in human or animal blood.

Does exercise change how long MOTS-c stays active in the body?

Research shows circulating MOTS-c levels rise in response to exercise-induced metabolic stress, consistent with a mitohormetic signaling loop described in a 2022 Diabetes & Metabolism Journal review (PMID 35656563). This describes concentration changes with a physiological trigger, not a formal half-life measurement.

Is MOTS-c really 'exercise in a pill'?

No, that's marketing framing, not a finding. Research shows MOTS-c mimics specific downstream signaling pathways activated by exercise, such as AMPK activation and Nrf2 signaling in disease models (PMID 40425777). Nobody has shown that dosing MOTS-c in healthy humans replicates the full physiological effect of a workout.

Why hasn't a human pharmacokinetic study been done for MOTS-c yet?

MOTS-c is not an FDA-approved drug (verifiable via Drugs@FDA), and formal PK studies with serial blood draws are typically required as part of drug approval pathways, not compounding. Since MOTS-c hasn't gone through that pipeline, no sponsor has been required to generate human half-life data.

Does MOTS-c's half-life differ from other longevity peptides?

We can't make that comparison numerically because no published human half-life exists for MOTS-c. A 2026 Sports Medicine review (PMID 41966639) groups peptides by regulatory and evidence status; MOTS-c falls in the less-characterized, non-FDA-approved category alongside many other gray-market research peptides.

Can blood work show how much MOTS-c is still in my system?

Standard clinical labs don't typically measure MOTS-c levels directly; they're not part of routine metabolic panels. For what markers are actually worth monitoring while using MOTS-c, see MOTS-c and blood work.

Is there a reliable MOTS-c half-life number in animal studies?

Most animal studies report downstream effects (glucose handling, AMPK activation, gene expression changes) rather than a formal elimination half-life in minutes or hours. The 2018 Cell Metabolism nuclear translocation study (PMID 29983246) is a good example: it documents a mechanism, not a clearance rate.

Does the missing half-life data mean MOTS-c is unsafe?

Not necessarily, but it means safety monitoring and dosing intervals can't be precisely calibrated the way they are for approved drugs with known pharmacokinetics. It's a data gap, not a safety verdict. Treat it as a reason for caution and provider oversight rather than alarm.

Where can I find provider-reviewed sourcing given the unclear pharmacokinetics?

MOTS-c Co reviews providers who coordinate with pharmacy partners operating under FDA compounding frameworks (21 CFR 216.23/216.24) rather than unregulated vial sellers. See MOTS-c near me for how that route works and what to ask.

How does MOTS-c's unclear half-life affect pricing?

Pricing itself isn't set by pharmacokinetics, but vendors sometimes justify premium pricing with unverified 'extended half-life' or 'optimized formulation' claims. See MOTS-c cost and pricing for how to evaluate those claims against what's actually documented.

Sources

1. PubMed, Cell Metabolism 2015 (PMID 25738459): MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in mice
2. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): MOTS-c is characterized as a promising mitochondrial-derived peptide for therapeutic exploitation, reflecting its still-developing evidence base
3. PubMed, Cell Metabolism 2018 (PMID 29983246): MOTS-c translocates to the nucleus and regulates nuclear gene expression in response to metabolic stress
4. PubMed, BioEssays 2019 (PMID 31378979): MOTS-c functions as a mitochondrial-encoded regulator of the nucleus
5. FDA, Drugs@FDA database: MOTS-c does not appear as an FDA-approved drug product
6. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): MOTS-c is part of a mitohormetic signaling loop triggered by exercise-related metabolic stress
7. PubMed, Biochimica et Biophysica Acta 2021 (PMID 34520826): Exercise acutely changes circulating mitochondrial-derived peptide levels including MOTS-c
8. PubMed, Sports Medicine 2026 (PMID 41966639): Peptide therapies for athletic performance are grouped into FDA-approved and unapproved categories with differing evidence maturity
9. PubMed, Scientific Reports 2025 (PMID 40425777): MOTS-c mimics exercise-associated signaling to combat diabetic liver fibrosis via Keap1-Nrf2-Smad2/3 in an animal model
10. eCFR, 21 CFR 216.23: 21 CFR 216.23 establishes the bulk drug substances list for 503A pharmacy compounding
11. eCFR, 21 CFR 216.24: 21 CFR 216.24 establishes the bulk drug substances list for 503B outsourcing facility compounding
12. FDA, bulk drug substances used in compounding under section 503A: FDA maintains a bulk drug substances list governing what can be used in 503A compounding
13. FDA, bulk drug substances nominated for use in compounding (current list): FDA maintains a current list of nominated bulk drug substances under review for compounding use
14. Cornell Law, 21 U.S.C. 353a: 21 U.S.C. 353a establishes the legal framework for pharmacy compounding
15. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes mellitus model
16. PubMed, Experimental & Molecular Medicine 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes in a model
17. PubMed, iScience 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
18. PubMed, American Journal of Physiology 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling
19. PubMed, American Journal of Physiology 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
20. PubMed, Peptides 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro
21. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination
22. PubMed, Redox Biology 2025 (PMID 40403491): MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation
23. PubMed, Frontiers in Physiology 2023 (PMID 37200834): MOTS-c has a documented role in the regulation of bone metabolism
24. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c attenuates mitochondrial dysfunction, pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-dependent mechanism
25. PubMed, Gut 2024 (PMID 37788894): MOTS-c contributes an antiviral role during HBV infection via mitochondrial remodelling
26. PubMed, Rejuvenation Research 2018 (PMID 30058454): Mitochondrial-derived peptides as a class can exacerbate senescence in certain contexts studied